Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial

Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial

BackgroundThe first-line standard treatment option for patients with NSCLC complicated with Chronic obstructive pulmonary disease (COPD) is still unclear and relies on the treatment option of NSCLC alone. To date, a limited number of retrospective studies have explored the efficacy and safety of imm...

Full description

Bibliographic Details
Main Authors: Weigang Dong, Yan Yin, Bin Liu, Yan Jiang, Lei Wang, Dongsheng Shi, Jianwen Qin
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
chronic obstructive pulmonary disease
pembrolizumab
efficacy
safety
non-small cell lung cancer (NSCLC)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1179232/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1179232/full

Similar Items